Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 36 |
| Active Pipeline (Recruiting Now) | 18 (12) |
| Completed vs Stopped Early | 4 / 1 (2.8%) |
| Median Closed Actual Enrollment | 517 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 7 |
| Taizhou Hospital of Zhejiang Province | Taizhou, Zhejiang | 2 |
| Shengjing hospital of China medical university | Shenyang, Shenyang | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07292714 | A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Mabwell (Shanghai) Bioscience Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.